BG Medicine Posts 85 Percent Jump in Q1 Revenues, Appoints New CEO | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine today reported first quarter revenues of $888,000, up 85 percent from $480,000 in the first quarter of 2012.

The company also announced that it had appointed Paul Sohmer as president and CEO, replacing Eric Bouvier.

The revenue increase was driven by $820,000 in revenues from sales of the company's BGM Galectin-3 test, a 97 percent jump from the $416,000 it posted in Q1 2012. The remaining $68,000 in revenues came from BG's services business, up 6 percent from $64,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of some animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.